Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors

Author： Roca Sophie Quivy Amandine Gross-Goupil Marine Bernhard Jean-Christophe De Clermont Henri Ravaud Alain

ISSN： 0284-186X

Source： Acta Oncologica, Vol.50, Iss.7, 2011-10, pp. : 1135-1136

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Energy Balance, Polymorphisms in the mTOR Pathway, and Renal Cell Carcinoma Risk

By Shu Xiang Lin Jie Wood Christopher G. Tannir Nizar M. Wu Xifeng

Journal of the National Cancer Institute, Vol. 105, Iss. 6, 2013-03 ,pp. : 424-432

Oxford University Press

Access to resources Recommend Favorite

Interferonα enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity

Experimental and Therapeutic Medicine, Vol. 8, Iss. 1, 2014-01 ,pp. : 267-273

Spandidos Publications

Access to resources Recommend Favorite

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

By Pal Sumanta

Targeted Oncology, Vol. 6, Iss. 1, 2011-03 ,pp. : 5-16

Springer Publishing Company

Access to resources Recommend Favorite

Updates of mTOR Inhibitors

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 10, Iss. 7, 2010-09 ,pp. : 571-581

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting mTOR in cancer: renal cell is just a beginning

By Azim Hamdy

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 269-280

Springer Publishing Company

Access to resources Recommend Favorite